Department of Neurosurgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, South Korea.
Neuro Oncol. 2013 Aug;15(8):1096-101. doi: 10.1093/neuonc/not069. Epub 2013 Jun 25.
To determine the benefit of surgical management in recurrent glioblastoma, we analyzed a series of patients with recurrent glioblastoma who had undergone surgery, and we devised a new scale to predict their survival.
Clinical data from 55 consecutive patients with recurrent glioblastoma were evaluated after surgical management. Kaplan-Meier survival analysis and Cox proportional hazards regression modeling were used to identify prognostic variables for the development of a predictive scale. After the multivariate analysis, performance status (P = .078) and ependymal involvement (P = .025) were selected for inclusion in the new prognostic scale. The devised scale was validated with a separate set of 96 patients from 3 different institutes.
A 3-tier scale (scoring range, 0-2 points) composed of additive scores for the Karnofsky performance status (KPS) (0 for KPS ≥ 70 and 1 for KPS < 70) and ependymal involvement (0 for no enhancement and 1 for enhancement of the ventricle wall in the magnetic resonance imaging) significantly distinguished groups with good (0 points; median survival, 18.0 months), intermediate (1 point; median survival, 10.0 months), and poor prognoses (2 points; median survival, 4.0 months). The new scale was successfully applied to the validation cohort of patients showing distinct prognosis among the groups (median survivals of 11.0, 9.0, and 4.0 months for the 0-, 1-, and 2-point groups, respectively).
We developed a practical scale to facilitate deciding whether to proceed with surgical management in patients with recurrent glioblastoma. This scale was useful for the diagnosis of prognostic groups and can be used to develop guidelines for patient treatment.
为了确定复发性胶质母细胞瘤手术治疗的获益,我们分析了一组接受手术治疗的复发性胶质母细胞瘤患者,并设计了一种新的评分系统来预测他们的生存情况。
对 55 例接受复发性胶质母细胞瘤手术治疗的连续患者的临床资料进行评估。采用 Kaplan-Meier 生存分析和 Cox 比例风险回归模型来确定用于预测评分的预后变量。经过多变量分析,选择表现状态(P=0.078)和室管膜受累(P=0.025)纳入新的预后评分。利用来自 3 个不同研究所的 96 例患者的独立数据集验证所设计的评分。
由卡氏功能状态评分(KPS)(KPS≥70 为 0 分,KPS<70 为 1 分)和室管膜受累(无增强为 0 分,磁共振成像中脑室壁增强为 1 分)的加和得分组成的 3 级评分(评分范围 0-2 分),显著区分了预后良好(0 分;中位生存期 18.0 个月)、预后中等(1 分;中位生存期 10.0 个月)和预后不良(2 分;中位生存期 4.0 个月)的患者组。该新评分成功应用于患者验证队列,显示出组间的明显预后差异(0-、1-和 2-分组的中位生存期分别为 11.0、9.0 和 4.0 个月)。
我们开发了一种实用的评分系统,以方便决定是否对复发性胶质母细胞瘤患者进行手术治疗。该评分系统有助于对预后组进行诊断,可用于制定患者治疗指南。